Lirum Therapeutics Presents Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against a Range of Pediatric Cancers
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage…